

Michael A Caligiuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4356619/publications.pdf>

Version: 2024-02-01

134
papers

17,770
citations

28274

55
h-index

15732

125
g-index

139
all docs

139
docs citations

139
times ranked

19430
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Fc Receptor-Mediated Effects and the “Don’t Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 201-214.	7.0	31
2	The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. <i>Journal of Virology</i> , 2022, 96, JVI0096421.	3.4	84
3	Off-the-Shelf Prostate Stem Cell Antigen-“Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. <i>Gastroenterology</i> , 2022, 162, 1319-1333.	1.3	38
4	PDGF- α ~PDGFR β signaling enhances IL-15-mediated human natural killer cell survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	14
5	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 154-169.	5.0	8
6	A four-stage model for murine natural killer cell development in vivo. <i>Journal of Hematology and Oncology</i> , 2022, 15, 31.	17.0	4
7	Adipocyte CD1d Gene Transfer Induces T Cell Expansion and Adipocyte Inflammation in CD1d Knockout Mice. <i>Journal of Immunology</i> , 2022, 208, 2109-2121.	0.8	2
8	ILC1s control leukemia stem cell fate and limit development of AML. <i>Nature Immunology</i> , 2022, 23, 718-730.	14.5	22
9	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. <i>Nature Communications</i> , 2022, 13, 2576.	12.8	21
10	Enriched environment enhances NK cell maturation through hypothalamic BDNF in male mice. <i>European Journal of Immunology</i> , 2021, 51, 557-566.	2.9	6
11	Oncolytic HSV Vectors and Anti-Tumor Immunity. <i>Current Issues in Molecular Biology</i> , 2021, 41, 381-468.	2.4	8
12	Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 320.	3.7	6
13	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. <i>Cell Reports Medicine</i> , 2021, 2, 100189.	6.5	149
14	An Oncolytic Virus Expressing IL15/IL15R β Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. <i>Cancer Research</i> , 2021, 81, 3635-3648.	0.9	89
15	Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease. <i>Vaccines</i> , 2021, 9, 555.	4.4	3
16	Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2021, 138, 1465-1480.	1.4	34
17	The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	82
18	Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers. <i>Oncologist</i> , 2021, 26, 533-536.	3.7	16

#	ARTICLE	IF	CITATIONS
19	Enhancing Effects of Environmental Enrichment on the Functions of Natural Killer Cells in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 695859.	4.8	10
20	Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation. <i>Cancer Immunology Research</i> , 2021, 9, 1229-1241.	3.4	14
21	Environmental activation of a hypothalamic BDNF-adipocyte IL-15 axis regulates adipose-natural killer cells. <i>Brain, Behavior, and Immunity</i> , 2021, 95, 477-488.	4.1	5
22	Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation from a Common Precursor. <i>Journal of Immunology</i> , 2021, 207, 1672-1682.	0.8	6
23	Evidence generation and reproducibility in cell and gene therapy research: A call to action. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 11-14.	4.1	13
24	Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells. <i>Journal of Immunology</i> , 2021, 206, 677-685.	0.8	10
25	CD84 is a regulator of the immunosuppressive microenvironment in Multiple Myeloma. <i>JCI Insight</i> , 2021, 6, .	5.0	15
26	An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. <i>Nature Communications</i> , 2021, 12, 5908.	12.8	56
27	Notch Regulates Innate Lymphoid Cell Plasticity during Human NK Cell Development. <i>Journal of Immunology</i> , 2020, 205, 2679-2693.	0.8	17
28	Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 168.	17.0	114
29	Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12332-12340.	7.1	28
30	Oncolytic HSV-1 Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 2381-2392.	7.0	23
31	Editorial: Natural Killer Cells in Tissue Compartments. <i>Frontiers in Immunology</i> , 2020, 11, 258.	4.8	7
32	CSF1R inhibitor PLX5622 and environmental enrichment additively improve metabolic outcomes in middle-aged female mice. <i>Aging</i> , 2020, 12, 2101-2122.	3.1	22
33	Role of Mir-29b in T-Cell Development and in Cutaneous T-Cell Lymphoma Pathogenesis. <i>Blood</i> , 2020, 136, 37-37.	1.4	0
34	Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 39-39.	1.4	0
35	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. <i>Nature</i> , 2019, 572, 254-259.	27.8	246
36	The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. <i>Cancer Discovery</i> , 2019, 9, 1422-1437.	9.4	210

#	ARTICLE	IF	CITATIONS
37	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4955-4965.	7.0	30
38	Adipocytes: A Novel Target for IL-15/IL-15R α Cancer Gene Therapy. <i>Molecular Therapy</i> , 2019, 27, 922-932.	8.2	25
39	CSIG-23. NOTCH ACTIVATION INDUCED BY HSV-1 ENCODED miRNA-H16 SENSITIZES α HSV-TREATED TUMORS TO NOTCH INHIBITOR. <i>Neuro-Oncology</i> , 2019, 21, vi49-vi49.	1.2	0
40	Cellular pathways in the development of human and murine innate lymphoid cells. <i>Current Opinion in Immunology</i> , 2019, 56, 100-106.	5.5	54
41	An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. <i>Nature Biotechnology</i> , 2019, 37, 45-54.	17.5	56
42	The IL-15 α -AKT β -XBP1s signaling pathway contributes to effector functions and survival in human NK cells. <i>Nature Immunology</i> , 2019, 20, 10-17.	14.5	83
43	Enriched environment regulates thymocyte development and alleviates experimental autoimmune encephalomyelitis in mice. <i>Brain, Behavior, and Immunity</i> , 2019, 75, 137-148.	4.1	31
44	FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2722-2722.	1.4	0
45	Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. <i>Clinical Cancer Research</i> , 2018, 24, 3273-3281.	7.0	20
46	Complex role of NK cells in regulation of oncolytic virus α -bortezomib therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4927-4932.	7.1	52
47	Patient Enrichment for Precision α -Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 23-26.	4.7	17
48	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. <i>Haematologica</i> , 2018, 103, 982-987.	3.5	16
49	Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. <i>Journal of Immunology</i> , 2018, 200, 565-572.	0.8	33
50	SMAD4 promotes TGF- β α -independent NK cell homeostasis and maturation and antitumor immunity. <i>Journal of Clinical Investigation</i> , 2018, 128, 5123-5136.	8.2	55
51	Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. <i>Blood</i> , 2018, 132, 1792-1804.	1.4	66
52	CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. <i>Immunity</i> , 2018, 49, 464-476.e4.	14.3	86
53	A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. <i>Cancer Immunology Research</i> , 2018, 6, 776-787.	3.4	83
54	Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 183.	4.8	20

#	ARTICLE	IF	CITATIONS
55	Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e300-e304.	3.5	2
56	Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 312-322.	4.1	101
57	IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF- κ B. <i>Journal of Immunology</i> , 2017, 199, 2333-2342.	0.8	80
58	The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. <i>Immunity</i> , 2017, 47, 159-170.e10.	14.3	27
59	The Broad Spectrum of Human Natural Killer Cell Diversity. <i>Immunity</i> , 2017, 47, 820-833.	14.3	485
60	BA11 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 1809-1819.	7.0	29
61	Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2017, 8, 360.	4.8	112
62	Ibrutinib treatment improves T cell number and function in CLL patients. <i>Journal of Clinical Investigation</i> , 2017, 127, 3052-3064.	8.2	280
63	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. <i>Cell Reports</i> , 2016, 16, 379-391.	6.4	100
64	Obesity, Inflammation, and Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 421-449.	22.4	570
65	Environmental and Genetic Activation of Hypothalamic BDNF Modulates T-cell Immunity to Exert an Anticancer Phenotype. <i>Cancer Immunology Research</i> , 2016, 4, 488-497.	3.4	42
66	A Progenitor Cell Expressing Transcription Factor ROR γ t Generates All Human Innate Lymphoid Cell Subsets. <i>Immunity</i> , 2016, 44, 1140-1150.	14.3	153
67	Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. <i>Blood</i> , 2016, 127, 2879-2889.	1.4	80
68	Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S181-S190.e4.	0.4	7
69	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. <i>Cancer Discovery</i> , 2016, 6, 986-1005.	9.4	79
70	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. <i>Cancer Research</i> , 2016, 76, 2125-2136.	0.9	150
71	MicroRNA-29b mediates altered innate immune development in acute leukemia. <i>Journal of Clinical Investigation</i> , 2016, 126, 4404-4416.	8.2	51
72	Biallelic mutations in IRF8 impair human NK cell maturation and function. <i>Journal of Clinical Investigation</i> , 2016, 127, 306-320.	8.2	76

#	ARTICLE	IF	CITATIONS
73	Rapid Column-Free Enrichment of Mononuclear Cells from Solid Tissues. <i>Scientific Reports</i> , 2015, 5, 12490.	3.3	11
74	The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development. <i>Cancer Immunology Research</i> , 2015, 3, 787-794.	3.4	23
75	PTEN Is a Negative Regulator of NK Cell Cytolytic Function. <i>Journal of Immunology</i> , 2015, 194, 1832-1840.	0.8	37
76	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. <i>Scientific Reports</i> , 2015, 5, 11483.	3.3	270
77	Transcription Factor Foxo1 Is a Negative Regulator of Natural Killer Cell Maturation and Function. <i>Immunity</i> , 2015, 42, 457-470.	14.3	141
78	The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. <i>Journal of Immunology</i> , 2015, 195, 1995-2005.	0.8	25
79	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3 , GATA6 , and TWIST1 in the Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2084-2092.	0.7	32
80	TGF β 2 Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. <i>Cancer Research</i> , 2015, 75, 5273-5282.	0.9	75
81	Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2044-2050.	7.0	166
82	Human natural killer cell development in secondary lymphoid tissues. <i>Seminars in Immunology</i> , 2014, 26, 132-137.	5.6	126
83	The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells. <i>Cell Reports</i> , 2014, 8, 150-162.	6.4	84
84	The Natural Product Phyllanthusin C Enhances IFN- γ Production by Human NK Cells through Upregulation of TLR-Mediated NF- κ B Signaling. <i>Journal of Immunology</i> , 2014, 193, 2994-3002.	0.8	46
85	Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. <i>Blood</i> , 2014, 124, 1127-1135.	1.4	55
86	The Epstein-Barr Virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development. <i>Blood</i> , 2014, 124, 4144-4144.	1.4	0
87	Location and cellular stages of natural killer cell development. <i>Trends in Immunology</i> , 2013, 34, 573-582.	6.8	288
88	Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. <i>Blood</i> , 2012, 120, 1130-1136.	1.4	74
89	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2012, 120, 4324-4333.	1.4	217
90	Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation. <i>Cancer Cell</i> , 2012, 22, 645-655.	16.8	150

#	ARTICLE	IF	CITATIONS
91	NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. <i>Nature Medicine</i> , 2012, 18, 1827-1834.	30.7	164
92	Evidence for a stepwise program of extrathymic T cell development within the human tonsil. <i>Journal of Clinical Investigation</i> , 2012, 122, 1403-1415.	8.2	77
93	The Clinical Role of Micrnas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). <i>Blood</i> , 2012, 120, 1387-1387.	1.4	1
94	Human Natural Killer (NK) Cells: Differential Expression of Phosphatase and Tensin Homologue Deleted On Chromosome Ten (PTEN) During NK Cell Development Regulates Its Cytolytic Activity Against Leukemic Target Cells. <i>Blood</i> , 2012, 120, 254-254.	1.4	1
95	NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. <i>Journal of Clinical Investigation</i> , 2011, 121, 1456-1470.	8.2	58
96	MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBF β) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion. <i>Blood</i> , 2011, 118, 2801-2801.	1.4	4
97	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 236-236.	1.4	0
98	A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. <i>Leukemia Research</i> , 2010, 34, 203-209.	0.8	18
99	Interleukin-1 β Selectively Expands and Sustains Interleukin-22+ Immature Human Natural Killer Cells in Secondary Lymphoid Tissue. <i>Immunity</i> , 2010, 32, 803-814.	14.3	180
100	In Vivo Role of Flt3 Ligand and Dendritic Cells in NK Cell Homeostasis. <i>Journal of Immunology</i> , 2010, 184, 2769-2775.	0.8	50
101	CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. <i>Blood</i> , 2010, 115, 274-281.	1.4	228
102	Effective Targeting of Acute Myeloid Leukemia (AML) Harboring the FLT3 ITD Mutation through the Axl/Gas6 Pathway. <i>Blood</i> , 2010, 116, 500-500.	1.4	1
103	The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. <i>Blood</i> , 2009, 113, 2470-2477.	1.4	59
104	Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH17 cytokine interleukin-22. <i>Blood</i> , 2009, 113, 4008-4010.	1.4	108
105	Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. <i>Blood</i> , 2009, 114, 2667-2677.	1.4	363
106	Human natural killer cells. <i>Blood</i> , 2008, 112, 461-469.	1.4	1,572
107	TGF- β Utilizes SMAD3 to Inhibit CD16-Mediated IFN- γ Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells. <i>Journal of Immunology</i> , 2008, 181, 3784-3792.	0.8	201
108	Characterization of An NKp46+ NKT Subset Which Is Susceptible to Malignant Transformation in Vivo.. <i>Blood</i> , 2008, 112, 1546-1546.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells. <i>Immunity</i> , 2006, 24, 575-590.	14.3	235
110	Human natural killer cell development. <i>Immunological Reviews</i> , 2006, 214, 56-72.	6.0	405
111	Evidence for discrete stages of human natural killer cell differentiation in vivo. <i>Journal of Experimental Medicine</i> , 2006, 203, 1033-1043.	8.5	370
112	NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL. <i>Blood</i> , 2006, 108, 135-135.	1.4	3
113	A Phase II Study of the TNF- α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.. <i>Blood</i> , 2006, 108, 2841-2841.	1.4	4
114	A Human CD34(+) Subset Resides in Lymph Nodes and Differentiates into CD56brightNatural Killer Cells. <i>Immunity</i> , 2005, 22, 295-304.	14.3	331
115	Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells. <i>Advances in Immunology</i> , 2005, 86, 209-239.	2.2	260
116	ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. <i>Blood</i> , 2005, 106, 1992-1992.	1.4	8
117	Immunotherapeutic Approaches for Hematologic Malignancies. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 337-353.	2.5	31
118	Elucidation of the Molecular Mechanisms by Which Inflammatory and Anti-Inflammatory Monokines Regulate Interferon (IFN)- γ Production.. <i>Blood</i> , 2004, 104, 111-111.	1.4	2
119	Efficient and Reproducible Retroviral Infection of Primary Human Natural Killer Cells.. <i>Blood</i> , 2004, 104, 1348-1348.	1.4	0
120	Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.. <i>Blood</i> , 2004, 104, 476-476.	1.4	3
121	A Phase II Study of the TNF- α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.. <i>Blood</i> , 2004, 104, 3469-3469.	1.4	1
122	Coordinated and Distinct Roles for IFN- γ , IL-12, and IL-15 Regulation of NK Cell Responses to Viral Infection. <i>Journal of Immunology</i> , 2002, 169, 4279-4287.	0.8	544
123	In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. <i>Blood</i> , 2002, 100, 3633-3638.	1.4	382
124	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. <i>Blood</i> , 2002, 100, 1935-1947.	1.4	449
125	Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications. <i>International Reviews of Immunology</i> , 2001, 20, 503-536.	3.3	33
126	Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. <i>Blood</i> , 2001, 97, 3146-3151.	1.4	1,201

#	ARTICLE	IF	CITATIONS
127	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells. <i>European Journal of Immunology</i> , 2001, 31, 3016-3025.	2.9	141
128	Interleukin 15: biology and relevance to human disease. <i>Blood</i> , 2001, 97, 14-32.	1.4	851
129	The biology of human natural killer-cell subsets. <i>Trends in Immunology</i> , 2001, 22, 633-640.	6.8	2,520
130	Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells. <i>Journal of Experimental Medicine</i> , 2001, 193, 219-232.	8.5	335
131	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells. , 2001, 31, 3016.		3
132	Molecular and Clinical Advances in Core Binding Factor Primary Acute Myeloid Leukemia: A Paradigm for Translational Research in Malignant Hematology. <i>Cancer Investigation</i> , 2000, 18, 768-780.	1.3	51
133	Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. <i>Oncogene</i> , 1999, 18, 3159-3165.	5.9	54
134	A review of the association between interleukin-10 and human B-cell malignancies. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 239-244.	4.2	58